Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
暂无分享,去创建一个
David Bruce Lewis | R. Guy | P. Read | A. McNulty | J. Amin | D. Templeton | A. Grulich | N. Dharan | M. Bloch | N. Doong | Don E. Smith | A. Carr | I. Zablotska | B. Bavinton | K. Brown | C. Selvey | K. Price | D. Baker | R. Finlayson | N. Ryder | C. Ooi | B. Yeung | F. Jin | C. Carmody | C. Power | Sarah J. Martin | David J Smith | S. Vaccher | M. Hammoud | Josephine Lusk | Gesalit Cabrera | Tobias Vickers | Erin Ogilvie | Shawn Clackett | E. Vlahakis | S. Martin | Daniel Chanisheff | Clara Tuck Meng Soo | T. Vickers
[1] David Bruce Lewis,et al. High Levels of Prevention-Effective Adherence to HIV PrEP: An Analysis of Substudy Data From the EPIC-NSW Trial , 2021, Journal of acquired immune deficiency syndromes.
[2] G. Prestage,et al. Australian Gay and Bisexual Men Who Use Condoms, PrEP or Rarely Practise HIV Risk Reduction with Casual Sex Partners: An Analysis of National, Behavioural Surveillance Data, 2017–2018 , 2020, AIDS and Behavior.
[3] Denton Callander,et al. Australian ‘gayborhoods’ and ‘lesborhoods’: a new method for estimating the number and prevalence of adult gay men and lesbian women living in each Australian postcode , 2020, Int. J. Geogr. Inf. Sci..
[4] S. Buchbinder,et al. PrEP Persistence is a Critical Issue in PrEP Implementation. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] V. Veloso,et al. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. , 2019, The lancet. HIV.
[6] E. Vittinghoff,et al. Racial/Ethnic and HIV risk category disparities in PrEP discontinuation among patients in publicly-funded primary care clinics. , 2019, AIDS.
[7] J. Baeten,et al. Global implementation of PrEP for HIV prevention: setting expectations for impact , 2019, Journal of the International AIDS Society.
[8] Z. R. Greenwald,et al. Cohort profile: l’Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada , 2019, BMJ Open.
[9] A. Siegler,et al. Persistence on HIV preexposure prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United States, 2015 to 2017 , 2019, Journal of the International AIDS Society.
[10] K. Mayer,et al. Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care , 2019, Journal of the International AIDS Society.
[11] D. Cooper,et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. , 2018, The lancet. HIV.
[12] M. Golden,et al. Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic , 2018, Sexually transmitted diseases.
[13] D. Cooper,et al. The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90‐90‐90 targets , 2018, Journal of the International AIDS Society.
[14] D. Cooper,et al. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial , 2018, BMC Public Health.
[15] D. Havlir,et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. , 2018, The lancet. HIV.
[16] A. McNulty,et al. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE , 2016, BMJ Open.
[17] Sheena McCormack,et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.
[18] M. Mimiaga,et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities , 2016, Journal of the International AIDS Society.
[19] M. Mimiaga,et al. Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM) , 2016, AIDS and Behavior.
[20] David Thompson,et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.
[21] J. Baeten,et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. , 2015, AIDS.
[22] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.